Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
Summary:
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle
Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies
Press Release
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle
Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies
From June 4-7 Novartis scientists participate in the World Congress of Cardiology & Cardiovascular Health (WCC) in Mexico. This Congress brings together thousands of heart health professionals from around the world. One of the key topics is rheumatic heart disease (RHD).
Blog written by Harald Nusser, Global Head Novartis Access
Blog
While the headlines might focus on Ebola or yellow fever, Africa is slowly winning the fight against infectious diseases. They will remain a challenge for decades to come, but the real threat of the future is expected to come from elsewhere: non-communicable diseases (NCDs) like diabetes, cardiovascular disease and cancer.
Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Summary:
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation
Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers
Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact
Press Release
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation
Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers
Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact
Malaria is still one of the most deadly diseases in developing countries
Article
Today is World Malaria Day. Malaria is preventable and curable, yet it is still one of the most deadly diseases in developing countries. Despite extraordinary progress in the fight against malaria over the last 15 years, the disease still claims the life of a child every two minutes.
The Novartis Institute for Tropical Diseases convenes parasitology experts in Zambia
Article
On April 4-8 2016, the Novartis Institute for Tropical Diseases (NITD) held a Symposium on Parasitology in Lusaka, Zambia, bringing together international and local experts in the field with the aim of engaging in productive scientific exchange on parasitic diseases - including malaria, sleeping sickness (Human African Trypanosomiasis), Chagas, leishmaniasis, and cryptosporidiosis.
Novartis will provide medicines for high blood pressure and diabetes
Article
Syrian refugees in Lebanon suffering from chronic diseases face difficulties accessing diagnosis, medicines and ongoing care. The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up for refugees, as well as members of their Lebanese host families, who suffer from chronic diseases.
Shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer
Article
We are pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer. The medicines are currently stored in the MEDS warehouse (Mission for Essential Drugs and Supplies) in Nairobi. MEDS is a faith-based not-for-profit medical supply chain and capacity building organization in Kenya.
Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.
